Category: Markets
Published: 2026-06-28T20:01:55.000Z
Regeneron Pharmaceuticals, Inc. (REGN) is being considered among the top AI-powered healthcare stocks by hedge funds after the FDA and European Medicines Agency accepted regulatory applications for its drug, cemdisiran, for generalized myasthenia gravis. The company expects FDA approval by November 2026 and a European Commission decision in the second half of 2027. Despite a "Sector Perform" rating from RBC Capital due to competition from AbbVie's acquisition of Apogee Therapeutics, the article suggests other AI stocks might offer greater return potential.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.